A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease

Harald Hampel, Filippo Caraci, A. Claudio Cuello, Giuseppe Caruso, Robert Nisticò, Massimo Corbo, Filippo Baldacci, Nicola Toschi, Francesco Garaci, Patrizia A. Chiesa, Steven Verdooner, Leyla Akman-Anderson, Félix Hernández, Jesús Ávila, Enzo Emanuele, Pedro L. Valenzuela, Alejandro Lucía, Mark Watling, Bruno P. Imbimbo, Andrea Vergallo, Simone ListaFrontiers in Immunology 2020 · DOI

Abstract

Neuroinflammation commences decades before Alzheimer's disease (AD) clinical onset and represents one of the earliest pathomechanistic alterations throughout the AD continuum. Large-scale genome-wide association studies point out several genetic variants—TREM2, CD33, PILRA, CR1, MS4A, CLU, ABCA7, EPHA1, and HLA-DRB5-HLA-DRB1—potentially linked to neuroinflammation. Most of these genes are involved in proinflammatory intracellular signaling, cytokines/interleukins/cell turnover, synaptic activity, lipid metabolism, and vesicle trafficking. Proteomic studies indicate that a plethora of interconnected aberrant molecular pathways, set off and perpetuated by TNF-α, TGF-β, IL-1β, and the receptor protein TREM2, are involved in neuroinflammation. Microglia and astrocytes are key cellular drivers and regulators of neuroinflammation. Under physiological conditions, they are important for neurotransmission and synaptic homeostasis. In AD, there is a turning point throughout its pathophysiological evolution where glial cells sustain an overexpressed inflammatory response that synergizes with amyloid-β and tau accumulation, and drives synaptotoxicity and neurodegeneration in a self-reinforcing manner. Despite a strong therapeutic rationale, previous clinical trials investigating compounds with anti-inflammatory properties, including non-steroidal anti-inflammatory drugs (NSAIDs), did not achieve primary efficacy endpoints. It is conceivable that study design issues, including the lack of diagnostic accuracy and biomarkers for target population identification and proof of mechanism, may partially explain the negative outcomes. However, a recent meta-analysis indicates a potential biological effect of NSAIDs. In this regard, candidate fluid biomarkers of neuroinflammation are under analytical/clinical validation, i.e., TREM2, IL-1β, MCP-1, IL-6, TNF-α receptor complexes, TGF-β, and YKL-40. PET radio-ligands are investigated to accomplish in vivo and longitudinal regional exploration of neuroinflammation. Biomarkers tracking different molecular pathways (body fluid matrixes) along with brain neuroinflammatory endophenotypes (neuroimaging markers), can untangle temporal-spatial dynamics between neuroinflammation and other AD pathophysiological mechanisms. Robust biomarker-drug codevelopment pipelines are expected to enrich large-scale clinical trials testing new-generation compounds active, directly or indirectly, on neuroinflammatory targets and displaying putative disease-modifying effects: novel NSAIDs, AL002 (anti-TREM2 antibody), anti-Aβ protofibrils (BAN2401), and AL003 (anti-CD33 antibody). As a next step, taking advantage of breakthrough and multimodal techniques coupled with a systems biology approach is the path to pursue for developing individualized therapeutic strategies targeting neuroinflammation under the framework of precision medicine.

The Neuroinflammation Paradox

Despite decades of research, Alzheimer’s remains a global health crisis with no disease-modifying cure. While research has traditionally focused on Amyloid-beta (Aβ) and Tau proteins, clinical trials targeting these have seen high failure rates. This has shifted focus toward neuroinflammation, which is now recognized as a core driver of the disease rather than a secondary effect.

The "inflammation paradox" highlights a significant gap: epidemiological data shows that long-term users of non-steroidal anti-inflammatory drugs (NSAIDs) have a lower risk of AD, yet clinical trials using these same drugs to treat established AD have almost universally failed. These failures likely stem from poor timing (treating too late in the disease progression), patient heterogeneity, and a lack of biomarkers to prove target engagement in the brain.

Cellular Drivers and the Glial Turning Point

Microglia and astrocytes are the primary cellular regulators of neuroinflammation. Under physiological conditions, they maintain neurotransmission and synaptic homeostasis. However, in AD, these cells reach a critical "turning point" where they shift from protective roles to sustaining a chronic, overexpressed inflammatory response.

Interplay between microglia, astrocytes, and neurons in the context of Aβ aggregation and neuroinflammation.

As illustrated in the figure above, glial cells interact with Aβ aggregates and extracellular vesicles (EVs), leading to the release of proinflammatory cytokines such as TNFα, IL1β, and C1q. This inflammatory environment synergizes with Aβ and tau accumulation to drive synaptotoxicity and neuronal apoptosis. Conversely, enzymes like IDE, MMP9, and neprilysin represent the brain's attempt at proteolytic degradation and phagocytosis of toxic aggregates. The balance between these protective and destructive pathways is a key target for future therapies.

Genetic and Molecular Landscape

Large-scale Genome-Wide Association Studies (GWAS) have identified several genetic variants—including TREM2 and CD33—that directly link the brain's innate immune system to AD pathogenesis. These genes are involved in proinflammatory signaling and cell turnover.

Recent breakthroughs in molecular targeting offer hope. For instance, the monoclonal antibody BAN2401 (anti-Aβ protofibrils) shows a 1,000-fold higher selectivity for toxic protofibrils compared to standard monomers, leading to significant reductions in brain amyloid in Phase 2 trials. Additionally, novel variants like XPro1595 can selectively neutralize soluble pro-inflammatory TNF without suppressing protective, membrane-bound TNF, potentially avoiding the side effects of older, non-selective TNF inhibitors.

Toward Precision Medicine: The A/T/N/I Framework

The Alzheimer Precision Medicine Initiative (APMI) advocates for a shift from "one-size-fits-all" treatments to a precision medicine approach. A key proposal is the expansion of the standard Amyloid/Tau/Neurodegeneration (A/T/N) classification to include an "I" for Inflammation.

Precision pharmacology aims to identify the right biological subgroup for specific treatments. Retrospective analyses suggest that a specific "proteomic signature" could predict NSAID response with up to 98% accuracy. This suggests that some "failed" drugs might actually be effective if administered to the correct patient population at the right disease stage, particularly before the irreversible glial turning point occurs.

Future Perspectives and P4 Medicine

The ultimate goal is the realization of "P4 Medicine"—Predictive, Preventive, Personalized, and Participatory. This requires shifting from treating "Alzheimer’s" as a monolithic disease to treating the specific molecular pathways active in an individual patient. By integrating multi-omic biomarkers (genomics, proteomics, metabolomics) with advanced neuroimaging, researchers can untangle the temporal-spatial dynamics of neuroinflammation and develop individualized therapeutic strategies.

Summary updated

Abstract

Neuroinflammation commences decades before Alzheimer's disease (AD) clinical onset and represents one of the earliest pathomechanistic alterations throughout the AD continuum. Large-scale genome-wide association studies point out several genetic variants-<i>TREM2, CD33, PILRA, CR1, MS4A, CLU, ABCA7, EPHA1</i>, and <i>HLA-DRB5-HLA-DRB1</i>-potentially linked to neuroinflammation. Most of these genes are involved in proinflammatory intracellular signaling, cytokines/interleukins/cell turnover, synaptic activity, lipid metabolism, and vesicle trafficking. Proteomic studies indicate that a plethora of interconnected aberrant molecular pathways, set off and perpetuated by TNF-α, TGF-β, IL-1β, and the receptor protein TREM2, are involved in neuroinflammation. Microglia and astrocytes are key cellular drivers and regulators of neuroinflammation. Under physiological conditions, they are important for neurotransmission and synaptic homeostasis. In AD, there is a turning point throughout its pathophysiological evolution where glial cells sustain an overexpressed inflammatory response that synergizes with amyloid-β and tau accumulation, and drives synaptotoxicity and neurodegeneration in a self-reinforcing manner. Despite a strong therapeutic rationale, previous clinical trials investigating compounds with anti-inflammatory properties, including non-steroidal anti-inflammatory drugs (NSAIDs), did not achieve primary efficacy endpoints. It is conceivable that study design issues, including the lack of diagnostic accuracy and biomarkers for target population identification and proof of mechanism, may partially explain the negative outcomes. However, a recent meta-analysis indicates a potential biological effect of NSAIDs. In this regard, candidate fluid biomarkers of neuroinflammation are under analytical/clinical validation, i.e., TREM2, IL-1β, MCP-1, IL-6, TNF-α receptor complexes, TGF-β, and YKL-40. PET radio-ligands are investigated to accomplish <i>in vivo</i> and longitudinal regional exploration of neuroinflammation. Biomarkers tracking different molecular pathways (body fluid matrixes) along with brain neuroinflammatory endophenotypes (neuroimaging markers), can untangle temporal-spatial dynamics between neuroinflammation and other AD pathophysiological mechanisms. Robust biomarker-drug codevelopment pipelines are expected to enrich large-scale clinical trials testing new-generation compounds active, directly or indirectly, on neuroinflammatory targets and displaying putative disease-modifying effects: novel NSAIDs, AL002 (anti-TREM2 antibody), anti-Aβ protofibrils (BAN2401), and AL003 (anti-CD33 antibody). As a next step, taking advantage of breakthrough and multimodal techniques coupled with a systems biology approach is the path to pursue for developing individualized therapeutic strategies targeting neuroinflammation under the framework of precision medicine.
BibTeX
@inproceedings{hampel2020path,
  author = {Harald Hampel and Filippo Caraci and A. Claudio Cuello and Giuseppe Caruso and Robert Nisticò and Massimo Corbo and Filippo Baldacci and Nicola Toschi and Francesco Garaci and Patrizia A. Chiesa and Steven Verdooner and Leyla Akman-Anderson and Félix Hernández and Jesús Ávila and Enzo Emanuele and Pedro L. Valenzuela and Alejandro Lucía and Mark Watling and Bruno P. Imbimbo and Andrea Vergallo and Simone Lista},
  title = {{A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease}},
  booktitle = {Frontiers in Immunology},
  year = {2020},
  doi = {10.3389/fimmu.2020.00456},
}
Figure